Filtered By:
Condition: Atrial Fibrillation
Procedure: Coronary Angioplasty
This page shows you your search results in order of relevance. This is page number 2.
Order by Relevance | Date
Total 376 results found since Jan 2013.
Stroke Risk Stratification With the CHADS2 Score in Patients Without Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention
The clinical significance of the CHADS2 score remains unclear in patients with coronary artery disease (CAD) without atrial fibrillation (AF). Therefore, the purpose of this study was to evaluate the association between the CHADS2 score and the long-term risk of ischemic stroke and its severity in patients with CAD with and without AF. Using the CREDO (Coronary Revascularization Demonstrating Outcome study)-Kyoto Registry Cohort-3, the present study population consisted of 11,516 patients with CAD who underwent percutaneous coronary intervention without oral anticoagulants at discharge.
Source: The American Journal of Cardiology - August 13, 2022 Category: Cardiology Authors: Yuki Obayashi, Hiroki Shiomi, Takeshi Morimoto, Yodo Tamaki, Moriaki Inoko, Ryusuke Nishikawa, Kazuhisa Kaneda, Ko Yamamoto, Yasuaki Takeji, Akihiro Komasa, Kyohei Yamaji, Satoshi Shizuta, Tomohisa Tada, Kazuya Nagao, Satoru Suwa, Toshihiro Tamura, Hiroki Source Type: research
Simultaneous thrombosis of 2 vascular territories: is thrombolytic therapy a better option?
We have read with great interest the article by Akyuz and colleagues in the American Journal of Emergency Medicine and congratulate them for their observation. Their case exemplifies the concurrent occurrence of ST-segment elevation myocardial infarction (STEMI) and posterior circulation stroke that was eventually managed with thrombolytic therapy. Simultaneous thrombosis of 2 distant vascular territories is a rare and complicated clinical scenario. In these instances, there is usually an underlying cause linking both thrombotic events rather than being a mere coincidence. We have previously described the myocardial infarc...
Source: The American Journal of Emergency Medicine - July 1, 2013 Category: Emergency Medicine Authors: Hesham R. Omar, Devanand Mangar, Enrico M. Camporesi Tags: Correspondence Source Type: research
Differential Occurrence, Profile, and Impact of First Recurrent Cardiovascular Events After an Acute Coronary Syndrome
Conclusions Approximately 9% of patients experienced a first cardiovascular event in the post-ACS setting during a median follow-up of 1year. While the profile and prognostic implications of stroke versus MI as the first nonfatal event differ substantially, approximately one-third of these patients experienced a second event, typically soon after the first event. These findings have implications for improving post-ACS care and influencing the design of future cardiovascular trials.
Source: American Heart Journal - February 20, 2017 Category: Cardiology Source Type: research
1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry
Conclusions
Intermediate to high-risk women enrolled in this first ever all-women contemporary TAVR registry experienced a 1-year VARC-2 composite efficacy endpoint of 16.5%, with a low incidence of 1-year mortality and stroke. Prior revascularization and EuroSCORE I were independent predictors of the VARC-2 efficacy endpoint, whereas EuroSCORE I, baseline atrial fibrillation, and prior percutaneous coronary intervention were independent predictors of the 1-year death or stroke.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - January 1, 2018 Category: Cardiology Authors: Chieffo, A., Petronio, A. S., Mehilli, J., Chandrasekhar, J., Sartori, S., Lefevre, T., Presbitero, P., Capranzano, P., Tchetche, D., Iadanza, A., Sardella, G., Van Mieghem, N. M., Meliga, E., Dumonteil, N., Fraccaro, C., Trabattoni, D., Mikhail, G., Shar Tags: Focus on Cardiovascular Outcomes Among Women Source Type: research
Atrial fibrillation in acute coronary syndrome: patient characteristics and appropriate utilisation of anti-thrombotic therapy in New Zealand (ANZACS-QI 39).
CONCLUSION: In New Zealand, one in seven patients presenting with ACS have AF, a third being new-onset AF. Antithrombotic management is inconsistent, with underutilisation of anticoagulants, particularly the DAT regimen, and is inadequately informed by stroke and bleeding risk scores.
PMID: 32777794 [PubMed - in process]
Source: New Zealand Medical Journal - August 12, 2020 Category: General Medicine Tags: N Z Med J Source Type: research
Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry
CONCLUSIONS: The AVIATOR 2 study is the first digital health study examining physician-patient perspectives on ATT choices after AF-PCI. TT was the most common strategy without differences in 1-year outcomes in ATT strategy. Physicians rated safety first when prescribing ATT; patients feared stroke over bleeding.CLINICALTRIALS: gov: NCT02362659.PMID:35656720 | DOI:10.4244/EIJ-D-21-01044
Source: EuroIntervention - June 3, 2022 Category: Cardiovascular & Thoracic Surgery Authors: Jaya Chandrasekhar Usman Baber Samantha Sartori Ridhima Goel Johny Nicolas Birgit Vogel Clayton Snyder Annapoorna Kini Carlo Briguori Bernhard Witzenbichler Ioannis Iakovou Gennaro Sardella Kevin Marzo Anthony DeFranco Thomas Stuckey Alaide Chieffo Antoni Source Type: research
Dual antiplatelet therapy versus oral anticoagulation plus dual antiplatelet therapy in patients with atrial fibrillation and low-to-moderate thromboembolic risk undergoing coronary stenting: Design of the MUSICA-2 randomized trial
Conclusions: The MUSICA-2 will attempt to determine the most effective and safe treatment in patients with nonvalvular AF and CHADS2 score ≤2 after PCI-S. Restricting TT for AF patients at high risk for stroke may reduce the incidence of bleeding without increasing the risk of thromboembolic complications.
Source: American Heart Journal - September 16, 2013 Category: Cardiology Authors: Antonia Sambola, J. Bruno Montoro, Bruno García del Blanco, Nadia Llavero, José A. Barrabés, Fernando Alfonso, Héctor Bueno, Angel Cequier, Antonio Serra, Javier Zueco, Manel Sabaté, Oriol Rodríguez-Leor, David García-Dorado Tags: Trial Design Source Type: research
Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment : A meta-analysis.
CONCLUSION: Our analysis found no statistically significant difference between TT and DT with regard to all-cause death and MACE/stroke risk. At the same time, the available data demonstrated that TT increased the risk of major bleeding. If the international normalized ratio is in the target range, the risk of bleeding may be lowered. The data from Asian countries were limited, and therefore we could not assess the difference between TT and DT in Asian populations. Finally,on the basis of our analysis, we do not recommend TT as conventional treatment for patients taking OACs and undergoing percutaneous coronary interventio...
Source: Herz - July 3, 2015 Category: Cardiology Tags: Herz Source Type: research
Utilization of Anticoagulant and Antiplatelet Agents Among Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention - Retrospective Cohort Study Using a Nationwide Claims Database in Japan.
CONCLUSIONS: Among Japanese AF patients who underwent PCI, prescriptions for antiplatelet agents were more common than those for anticoagulant agents. The majority of study participants were classified as high risk, suggesting a need for a new risk classification that reflects the risk profiles of Japanese patients.
PMID: 28883227 [PubMed - as supplied by publisher]
Source: Circulation Journal - September 7, 2017 Category: Cardiology Authors: Ono F, Tanaka S, Nakao YM, Kawakami K Tags: Circ J Source Type: research
Antithrombotic Therapy for Atrial Fibrillation and Coronary Disease de-Mystified
Publication date: Available online 20 August 2018Source: Canadian Journal of CardiologyAuthor(s): Jason G. Andrade, Marc W. Deyell, Graham C. Wong, Laurent MacleABSTRACTAtrial fibrillation (AF) is a progressive chronic disease characterized by exacerbations and periods of remission. It is estimated that up to 20-30% of those with AF also have coronary artery disease (CAD), and 5-15% will require percutaneous coronary intervention (PCI). In patients with concomitant AF and CAD, management remains challenging and requires a careful and balanced assessment of the risk of bleeding against the anticipated impact on ischemic out...
Source: Canadian Journal of Cardiology - August 21, 2018 Category: Cardiology Source Type: research
